 Emily Su
Concepts (194)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Placenta | 18 | 2023 | 628 | 5.230 |
Why?
| | Fetal Growth Retardation | 12 | 2023 | 468 | 4.460 |
Why?
| | Endothelial Cells | 10 | 2023 | 687 | 2.740 |
Why?
| | Estrogen Receptor beta | 6 | 2012 | 35 | 1.930 |
Why?
| | Neovascularization, Physiologic | 4 | 2021 | 173 | 1.690 |
Why?
| | Pregnancy | 25 | 2023 | 5520 | 1.210 |
Why?
| | Aryl Hydrocarbon Receptor Nuclear Translocator | 2 | 2019 | 15 | 1.140 |
Why?
| | Endometriosis | 6 | 2012 | 40 | 1.060 |
Why?
| | Premature Birth | 4 | 2023 | 276 | 1.040 |
Why?
| | Umbilical Arteries | 2 | 2015 | 41 | 0.960 |
Why?
| | Integrin alphaVbeta3 | 1 | 2022 | 20 | 0.820 |
Why?
| | Cell Movement | 4 | 2021 | 869 | 0.810 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 3 | 2022 | 66 | 0.760 |
Why?
| | Prostaglandins | 2 | 2011 | 77 | 0.700 |
Why?
| | Neovascularization, Pathologic | 2 | 2019 | 281 | 0.680 |
Why?
| | Fetus | 5 | 2023 | 700 | 0.660 |
Why?
| | Progesterone | 4 | 2010 | 232 | 0.660 |
Why?
| | Estrogens | 2 | 2012 | 312 | 0.650 |
Why?
| | Uveomeningoencephalitic Syndrome | 1 | 2019 | 6 | 0.640 |
Why?
| | 17-Hydroxysteroid Dehydrogenases | 2 | 2010 | 4 | 0.630 |
Why?
| | Adalimumab | 1 | 2019 | 44 | 0.630 |
Why?
| | Panuveitis | 1 | 2019 | 6 | 0.630 |
Why?
| | Extracellular Matrix | 1 | 2021 | 436 | 0.580 |
Why?
| | Pre-Eclampsia | 4 | 2023 | 165 | 0.570 |
Why?
| | Female | 36 | 2023 | 59520 | 0.540 |
Why?
| | Benzo(a)pyrene | 1 | 2016 | 7 | 0.540 |
Why?
| | Endothelium, Vascular | 5 | 2018 | 847 | 0.530 |
Why?
| | Cyclooxygenase 2 | 3 | 2016 | 164 | 0.520 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2016 | 39 | 0.520 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2022 | 498 | 0.520 |
Why?
| | Signal Transduction | 5 | 2019 | 4515 | 0.500 |
Why?
| | Endometrium | 4 | 2012 | 60 | 0.450 |
Why?
| | Reproduction | 2 | 2012 | 178 | 0.440 |
Why?
| | Cell Proliferation | 2 | 2018 | 2187 | 0.430 |
Why?
| | Stillbirth | 1 | 2013 | 57 | 0.420 |
Why?
| | Umbilical Cord | 1 | 2013 | 80 | 0.420 |
Why?
| | Fetal Diseases | 1 | 2013 | 147 | 0.390 |
Why?
| | Humans | 36 | 2023 | 114698 | 0.370 |
Why?
| | Endothelium | 1 | 2011 | 111 | 0.360 |
Why?
| | Hypertension | 3 | 2023 | 1056 | 0.360 |
Why?
| | Women's Health | 1 | 2012 | 271 | 0.330 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2007 | 270 | 0.320 |
Why?
| | Estradiol | 3 | 2011 | 455 | 0.320 |
Why?
| | Promegestone | 1 | 2007 | 33 | 0.290 |
Why?
| | Estrogen Receptor alpha | 3 | 2012 | 121 | 0.260 |
Why?
| | Fetal Development | 2 | 2023 | 248 | 0.260 |
Why?
| | Up-Regulation | 3 | 2019 | 808 | 0.260 |
Why?
| | Case-Control Studies | 4 | 2021 | 3003 | 0.240 |
Why?
| | Placental Circulation | 2 | 2017 | 56 | 0.240 |
Why?
| | Pregnancy Outcome | 3 | 2023 | 337 | 0.240 |
Why?
| | Infant, Newborn | 7 | 2023 | 5047 | 0.230 |
Why?
| | Uterus | 2 | 2017 | 192 | 0.220 |
Why?
| | Regional Blood Flow | 2 | 2017 | 424 | 0.210 |
Why?
| | Integrin alpha5beta1 | 1 | 2022 | 9 | 0.210 |
Why?
| | Cells, Cultured | 5 | 2021 | 3886 | 0.200 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 127 | 0.200 |
Why?
| | Epoprostenol | 2 | 2016 | 133 | 0.200 |
Why?
| | Stromal Cells | 3 | 2012 | 97 | 0.200 |
Why?
| | Fibronectins | 1 | 2022 | 108 | 0.200 |
Why?
| | Antihypertensive Agents | 2 | 2023 | 429 | 0.200 |
Why?
| | Trophoblasts | 2 | 2021 | 165 | 0.190 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2022 | 45 | 0.190 |
Why?
| | Furin | 1 | 2021 | 12 | 0.190 |
Why?
| | Receptors, Virus | 1 | 2021 | 75 | 0.180 |
Why?
| | Steroidogenic Factor 1 | 2 | 2012 | 6 | 0.180 |
Why?
| | Serine Endopeptidases | 1 | 2021 | 102 | 0.180 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 78 | 0.180 |
Why?
| | Receptors, Progesterone | 3 | 2012 | 319 | 0.180 |
Why?
| | Gestational Age | 4 | 2020 | 760 | 0.170 |
Why?
| | Breast Feeding | 1 | 2023 | 368 | 0.170 |
Why?
| | Models, Biological | 2 | 2017 | 1621 | 0.170 |
Why?
| | RNA Interference | 3 | 2011 | 433 | 0.160 |
Why?
| | Triamcinolone | 1 | 2019 | 14 | 0.160 |
Why?
| | Hypertension, Pulmonary | 2 | 2022 | 1729 | 0.160 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 102 | 0.150 |
Why?
| | Mycophenolic Acid | 1 | 2019 | 77 | 0.150 |
Why?
| | Remission Induction | 1 | 2019 | 233 | 0.150 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2018 | 86 | 0.150 |
Why?
| | Gene Expression Regulation | 3 | 2012 | 2320 | 0.150 |
Why?
| | Adult | 8 | 2021 | 30553 | 0.150 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 130 | 0.150 |
Why?
| | Headache | 1 | 2019 | 133 | 0.150 |
Why?
| | Fetal Blood | 2 | 2017 | 270 | 0.150 |
Why?
| | Research Design | 1 | 2023 | 928 | 0.150 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 923 | 0.140 |
Why?
| | Visual Acuity | 1 | 2019 | 274 | 0.140 |
Why?
| | Epigenesis, Genetic | 2 | 2012 | 520 | 0.140 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2016 | 30 | 0.130 |
Why?
| | Birth Weight | 2 | 2022 | 440 | 0.130 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 951 | 0.130 |
Why?
| | Maternal-Fetal Exchange | 1 | 2016 | 151 | 0.120 |
Why?
| | Ultrasonography, Doppler | 1 | 2015 | 105 | 0.120 |
Why?
| | Infant, Premature | 2 | 2017 | 476 | 0.110 |
Why?
| | Blood Flow Velocity | 1 | 2015 | 387 | 0.110 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2019 | 1140 | 0.110 |
Why?
| | Vascular Resistance | 1 | 2015 | 337 | 0.110 |
Why?
| | Growth Disorders | 1 | 2014 | 77 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2010 | 1141 | 0.110 |
Why?
| | Fetal Distress | 1 | 2012 | 12 | 0.100 |
Why?
| | Ovarian Diseases | 1 | 2012 | 12 | 0.100 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2017 | 329 | 0.100 |
Why?
| | Chorioamnionitis | 1 | 2012 | 36 | 0.100 |
Why?
| | Oogenesis | 1 | 2012 | 25 | 0.100 |
Why?
| | Ovulation | 1 | 2012 | 39 | 0.100 |
Why?
| | Eicosanoids | 1 | 2012 | 54 | 0.100 |
Why?
| | Estrogen Antagonists | 1 | 2012 | 39 | 0.100 |
Why?
| | Placentation | 1 | 2012 | 40 | 0.100 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2012 | 64 | 0.100 |
Why?
| | Pregnancy Proteins | 1 | 2012 | 36 | 0.100 |
Why?
| | Muscle Tonus | 1 | 2011 | 17 | 0.100 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2011 | 58 | 0.090 |
Why?
| | Parturition | 1 | 2012 | 54 | 0.090 |
Why?
| | Ultrasonography | 1 | 2015 | 634 | 0.090 |
Why?
| | Metabolic Networks and Pathways | 1 | 2012 | 168 | 0.090 |
Why?
| | Large Neutral Amino Acid-Transporter 1 | 1 | 2010 | 15 | 0.090 |
Why?
| | Vasoconstriction | 1 | 2011 | 177 | 0.090 |
Why?
| | Leiomyoma | 1 | 2010 | 44 | 0.090 |
Why?
| | Myometrium | 1 | 2010 | 35 | 0.090 |
Why?
| | Placenta Growth Factor | 2 | 2022 | 22 | 0.090 |
Why?
| | Uterine Neoplasms | 1 | 2010 | 73 | 0.080 |
Why?
| | Paracrine Communication | 1 | 2010 | 56 | 0.080 |
Why?
| | Apoptosis | 1 | 2018 | 2363 | 0.080 |
Why?
| | Thromboxanes | 1 | 2009 | 14 | 0.080 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 347 | 0.080 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 385 | 0.080 |
Why?
| | Blotting, Western | 1 | 2011 | 1147 | 0.080 |
Why?
| | Vasodilation | 1 | 2011 | 419 | 0.080 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 236 | 0.080 |
Why?
| | Breast Neoplasms | 2 | 2012 | 1862 | 0.080 |
Why?
| | Glucocorticoids | 1 | 2012 | 532 | 0.070 |
Why?
| | Retinoid X Receptor alpha | 1 | 2007 | 4 | 0.070 |
Why?
| | Progesterone Congeners | 1 | 2007 | 14 | 0.070 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1131 | 0.070 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2007 | 11 | 0.070 |
Why?
| | Aromatase | 1 | 2007 | 30 | 0.070 |
Why?
| | Receptors, Retinoic Acid | 1 | 2007 | 49 | 0.070 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1629 | 0.070 |
Why?
| | Animals | 4 | 2012 | 31708 | 0.070 |
Why?
| | Immunoblotting | 1 | 2007 | 283 | 0.070 |
Why?
| | Databases, Factual | 1 | 2011 | 1125 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 1 | 2007 | 397 | 0.070 |
Why?
| | Prospective Studies | 3 | 2022 | 6220 | 0.070 |
Why?
| | Cohort Studies | 3 | 2022 | 4895 | 0.060 |
Why?
| | Endometrial Neoplasms | 1 | 2007 | 141 | 0.060 |
Why?
| | Biomarkers | 3 | 2022 | 3408 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2010 | 2553 | 0.060 |
Why?
| | Cell Differentiation | 1 | 2010 | 1701 | 0.050 |
Why?
| | Ovarian Neoplasms | 1 | 2007 | 388 | 0.050 |
Why?
| | Abruptio Placentae | 1 | 2022 | 3 | 0.050 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2022 | 61 | 0.050 |
Why?
| | Chronic Disease | 2 | 2022 | 1578 | 0.050 |
Why?
| | Fetal Hypoxia | 1 | 2022 | 47 | 0.050 |
Why?
| | Virus Internalization | 1 | 2021 | 40 | 0.050 |
Why?
| | Postpartum Period | 1 | 2023 | 278 | 0.040 |
Why?
| | Child | 1 | 2019 | 18420 | 0.040 |
Why?
| | Middle Aged | 3 | 2013 | 26738 | 0.040 |
Why?
| | Altitude | 1 | 2022 | 432 | 0.040 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2021 | 288 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 1796 | 0.040 |
Why?
| | Blood Pressure | 1 | 2023 | 1538 | 0.030 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2017 | 71 | 0.030 |
Why?
| | Chorionic Villi | 1 | 2016 | 16 | 0.030 |
Why?
| | Proof of Concept Study | 1 | 2016 | 47 | 0.030 |
Why?
| | Microvilli | 1 | 2016 | 70 | 0.030 |
Why?
| | Infant, Extremely Premature | 1 | 2017 | 57 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2016 | 201 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2016 | 304 | 0.030 |
Why?
| | Adolescent | 1 | 2013 | 17853 | 0.030 |
Why?
| | Equipment Design | 1 | 2016 | 508 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 836 | 0.030 |
Why?
| | Mice | 1 | 2010 | 14871 | 0.030 |
Why?
| | Male | 3 | 2017 | 55606 | 0.030 |
Why?
| | Cardiotocography | 1 | 2012 | 3 | 0.030 |
Why?
| | Fetal Monitoring | 1 | 2012 | 16 | 0.030 |
Why?
| | Heart Rate, Fetal | 1 | 2012 | 20 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2012 | 118 | 0.020 |
Why?
| | Cell Line | 1 | 2016 | 2637 | 0.020 |
Why?
| | Cesarean Section | 1 | 2012 | 169 | 0.020 |
Why?
| | Mifepristone | 1 | 2010 | 60 | 0.020 |
Why?
| | Hormone Antagonists | 1 | 2010 | 33 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2387 | 0.020 |
Why?
| | CpG Islands | 1 | 2010 | 117 | 0.020 |
Why?
| | Acute Disease | 1 | 2012 | 911 | 0.020 |
Why?
| | Dinoprostone | 1 | 2008 | 184 | 0.020 |
Why?
| | Cell Survival | 1 | 2010 | 1021 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 1842 | 0.020 |
Why?
| | DNA Methylation | 1 | 2010 | 495 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2022 | 12555 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1518 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2540 | 0.010 |
Why?
| | United States | 1 | 2020 | 12186 | 0.010 |
Why?
| | Transcription Factors | 1 | 2008 | 1528 | 0.010 |
Why?
| | Inflammation | 1 | 2008 | 2480 | 0.010 |
Why?
| | Young Adult | 1 | 2012 | 10471 | 0.010 |
Why?
|
|
Su's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|